Читать книгу Здоровье без побочных эффектов - Питер Гётше - Страница 15

1. Available online at: http://en.wikiquote.org/wiki/William_Osler (accessed 30 August 2012).

2. Kelton E. More drug companies to pay billions for fraud, join the ‘dishonor roll’ after Abbott settlement. Forbes. 2012 May 10.

3. PhRMA Code on Interactions with Healthcare Professionals – Signatory Companies. Available online at: www.phrma.org/sites/default/fi les/108/signatory_companies_phrma_code_061112.pdf (accessed 25 June 2012).

4. Advertisement for Philip Morris International. Berlingske. 2004 Mar 14.

5. Rost P. The Whistleblower: confessions of a healthcare hitman. New York: Soft Skull Press; 2006.

6. Rockoff J.D., Matthews C.M. Pfizer settles federal bribery investigation. Wall Street Journal. 2012 Aug 7.

7. Reuters. Factbox – The 20 largest pharmaceutical companies. 2010 Mar 26.

8. Corporate Crime in the ’90s: the top 100 corporate criminals of the 1990s. Multinational Monitor. 1999 July/August; 20(7, 8).

9. Barboza D. Tearing down the facade of ‘Vitamins Inc.’. New York Times. 1999 Oct 10.

10. F. Hoffmann – La Roche and BASF Agree to Pay Record Criminal Fines for Participating in International Vitamin Cartel. US Department of Justice. 1999 May 20.

11. Mathiason N. Blowing the final whistle. The Guardian. 2001 Nov 25.

12. Braithwaite J. Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul; 1984.

13. Bobst E.H. Bobst: the autobiography of a pharmaceutical pioneer. New York: David McKay Company; 1973.

14. Bruun K. International drug control and the pharmaceutical industry. In: Cooperstock R, editor. Social Aspects of the Medical Use of Psychotropic Drugs. Toronto: Addiction Research Foundation of Ontario. Papers presented at the International Symposium on Alcohol and DrugResearch; 1973. Department of National Health and Welfare; 1974.

15. Nielsen M., Hansen E.H., Gøtzsche P.C. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction. 2012; 107: 900–8.

16. Healy D. Let Them Eat Prozac. New York: New York University Press; 2004.

17. House of Commons Health Committee. The Influence of the Pharmaceutical Industry. Fourth Report of Session 2004–05. Available online at: www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf (accessed 26 April 2005).

18. Abramson J. Overdosed America: the broken promise of American medicine. New York: HarperCollins; 2004.

19. Angell M. The Truth about the Drug Companies: how they deceive us and what to do about it. New York: Random House; 2004.

20. Kassirer J.P. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.

21. Mundy A. Dispensing with the Truth. New York: St. Martin’s Press; 2001.

22. Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.

23. Gøtzsche P.C. Big pharma often commits corporate crime, and this must be stopped. BMJ. 2012; 345: e8462.

24. Gøtzsche P.C. Corporate crime in the pharmaceutical industry is common, serious and repetitive. Available online at: www.cochrane.dk/research/corporatecrime/Corporate-crime-long-version.pdf (accessed 20 December 2012).

25. Pfizer agrees record fraud fine. BBC News. 2009 Sept 2.

26. Tanne J.H. Pfizer pays record fi ne for off-label promotion of four drugs. BMJ. 2009; 339: b3657.

27. Evans D. Big pharma’s crime spree. Bloomberg Markets. 2009 Dec: 72–86.

28. United States Department of Justice. Novartis Pharmaceuticals Corp. to Pay More than $420 million to Resolve Off-Label Promotion and Kickback Allegations. 2010 Sept 30.

29. SourceWatch. Sanofi – Aventis. 2011 Jan 23. Available online at: www.sourcewatch.org/index.phptitle=Sanofi – Aventis (accessed 19 June 2012).

30. Aventis to pay $95 million to settle fraud charge. AFP. 2009 May 28.

31. Rabiner S. Glaxo $3B fi ne largest healthcare fraud settlement in history? FindLaw. 2011 Nov 10.

32. United States Department of Justice. GlaxoSmithKline to Plead Guilty and Pay $3 billion to Resolve Fraud Allegations and Failure to Report Safety Data. 2012 July 2.

33. Thomas K., Schmidt M.S. Glaxo agrees to pay $3 billion in fraud settlement. New York Times. 2012 July 2.

34. Wilson D. Ex-Glaxo executive is charged in drug fraud. New York Times. 2010 Nov 9.

35. Khan H., Thomas P. Drug giant AstraZeneca to pay $520 million to settle fraud case. ABC News. 2010 April 27.

36. Tanne J.H. AstraZeneca pays $520m fi ne for off-label marketing. BMJ. 2010; 340: c2380.

37. Doshi P. Neuraminidase inhibitors: the story behind the Cochrane review. BMJ. 2009; 339: b5164.

38. Cohen D. Complications: tracking down the data on oseltamivir. BMJ. 2009; 339: b5387.

39. Cohen D., Carter P. WHO and the pandemic flu ‘conspiracies’. BMJ. 2012; 340: c2912.

40. Willman D. Relenza: official asks if one day less of flu is worth it. Los Angeles Times. 2000 Dec 20.

41. Epstein H. Flu warning: beware the drug companies! New York Review of Books. 2001 Apr 11.

42. Jefferson T., Jones M.A., Doshi P., et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2012; 1: CD008965.

43. Rennie D. Guarding the guardians: a conference on editorial peer review. JAMA. 1986; 256: 2391–2.

44. Doshi P, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med. 2012; 9: e1001201.

45. O’Dowd A. Response to swine flu was ‘unjustified’, says Council of Europe. BMJ. 2012; 340: c3033.

46. Gøtzsche P.C. European governments should sue Roche and prescribers should boycott its drugs. BMJ. 2012; 345: e7689.

47. Cohen D. Search for evidence goes on. BMJ. 2012; 344: e458.

48. Ark. judge fines Johnson & Johnson more than $1.1B in Risperdal case. CBS/AP. 2012 April 11.

49. Harris G. Research center tied to drug company. New York Times. 2008 Nov 25.

50. Kelton E. J&J needs a cure: new CEO allegedly had links to fraud. Forbes. 2012 17 April.

51. Silverman E. Merck to pay $670 million over Medicaid fraud. Pharmalot. 2008 Feb 7.

52. Reuters. The largest pharma fraud whistleblower case in U.S. history totaling $14 billion. 2009 Jan 15.

53. Anonymous. Abbott Labs to pay $15. billion more for Medicaid fraud. 2012 May 8. Available online at: http://somd.com/news/headlines/2012/15451.shtml (accessed 19 June 2012).

54. Roehr B. Abbott pays $1.6bn for promoting off label use of valproic acid. BMJ. 2012; 344: e3343.

55. Barnes K. Sanofi slammed by FDA over failure to act on Ketek fraud. Outsourcing. 2007 Oct 25.

56. Ross D.B. The FDA and the case of Ketek. N Engl J Med. 2007; 356: 1601–4.

57. Soreth J., Cox E., Kweder S., et al. Ketek – the FDA perspective. N Engl J Med. 2007; 356:1675–6.

58. Ketek Official FDA information, side effects and uses. Available online at: www.drugs.com/pro/ketek.html (accessed 18 Nov 2012).

59. Russell J. Johnson & Johnson feels pain of $75m bribery fines. The Telegraph. 2011 9 April.

60. Pringle E. Eli Lilly hides data: Zyprexa, Evista, Prozac risk. Conspiracy Planet. Available online at: www.conspiracyplanet.com/channel.cfm?channelid=55&contentid=4181&page=2 (accessed 28 June 2012).

61. Clinard M.B., Yeager P.C. Corporate Crime. New Brunswick: Transaction Publishers; 2006.

62. Harris G. As doctors write prescriptions, drug company writes a check. New York Times. 2004 June 27.

63. Lane C. Bad medicine: GlaxoSmithKline’s fraud and gross negligence. Psychology Today. 2011 Jan 7.

64. Silverman E. Glaxo to pay $750M for manufacturing fraud. Pharmalot. 2010 Oct 26.

65. Wikipedia. GlaxoSmithKline. Available online at: http://en.wikipedia.org/wiki/GlaxoSmithKline (accessed 20 June 2012).

66. Carpenter G. Italian doctors face charges over GSK incentive scheme. Over 4000 doctors are alleged to have received cash, gifts, and prizes to encourage them to prescribe GSK products. Lancet. 2004; 363: 1873.

67. Company news; drug maker agrees to pay $175 million in lawsuit. New York Times. 2004 Feb 7.

68. Prescription generics & patent management. Strategies in the Pharmaceutical Industry 2004. 2004 Nov 29.

69. Relman A.S., Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41.

70. Jack A. Legal tactics to delay launch of generic drugs cost Europe ′3bn. BMJ. 2008; 337: 1311.

71. Tanne J.H. Bristol-Myers Squibb made to pay $515 m to settle US law suits. BMJ. 2007; 335: 742–3.

72. Anonymous. Bristol-Myers will settle antitrust charges by U.S. New York Times. 2003 March 8.

73. Avorn J. Powerful Medicines: the benefits, risks, and costs of prescription drugs. New York: Vintage Books; 2005.

74. European Commission. Antitrust: Commission fines Lundbeck and other pharma companies for delaying market entry of generic medicines. Press release. 2013 June 19.

75. Abelson R. Whistle-blower suit says device maker generously rewards doctors. New York Times. 2006 Jan 24.

76. Poses R.M. Medtronic settles, yet again. Blog post. Health Care Renewal. 2011 Dec 15. Available online at: http://hcrenewal.blogspot.co.nz/2011/12/medtronic-settles-yet-again.html (accessed 10 July 2013).

77. Tanne J.H. US companies are fined for payments to surgeons. BMJ. 2007; 335: 1065.

78. Harris G., Pear R. Drug maker’s efforts to compete in lucrative insulin market are under scrutiny. New York Times. 2006 Jan 28.

79. Abelson R. How Schering manipulated drug prices and Medicaid. New York Times. 2004 July 31.

80. Harris G. Drug makers settled 7 suits by whistle-blowers, group says. New York Times. 2003 Nov 6.

81. OxyContin’s deception costs firm $634M. CBS News. 2007 May 10.

82. Zee A van. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am J Publ Health. 2009; 99: 221–7.

83. Wordsworth M. Deadly epidemic fears over common painkiller. ABC News. 2012 Nov 14.

84. Kendall B. Court backs crackdown on drug officials. Wall Street Journal. 2010 July 27.

85. Tansey B. Huge penalty in drug fraud: Pfizer settles felony case in Neurontin off-label promotion. San Francisco Chronicle. 2004 May 14.

86. Collier J. Big pharma and the UK government. Lancet. 2006; 367: 97–8.

87. Ferner R.E. The influence of big pharma. BMJ. 2005; 330: 857–8.

88. Smith R. Curbing the influence of the drug industry: a British view. PLoS Med. 2005; 2: e241.

89. Moynihan R. Officials reject claims of drug industry’s influence. BMJ. 2004; 329: 641.

90. Goldacre B. Bad Pharma. London: Fourth Estate; 2012.

91. Free Online Law Dictionary. Organized crime. Available online at: http://legal-dictionary.thefreedictionary.com/Organized+Crime (accessed 2 December 2012).

92. Peter Rost. Blog. Available online at: http://peterrost.blogspot.dk (accessed 26 June 2012).

93. Almashat S., Preston C., Waterman T., et al. Rapidly increasing criminal and civil monetary penalties against the pharmaceutical industry: 1991 to 2010. Public Citizen. 2010 Dec 16.

94. Almashat S., Wolfe S. Pharmaceutical industry criminal and civil penalties: an update. Public Citizen. 2012 Sept 27.